Literature DB >> 14740456

Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A.

F Atzeni1, P Sarzi-Puttini, F Capsoni, L Vulpio, M Carrabba.   

Abstract

We report a patient with longstanding systemic lupus erythematosus (SLE) who developed pure red cell aplasia (PRCA). This condition is rare in connective tissue diseases and is reported in 32 previous cases of SLE in literature. Our patient recovered, apparently in response to treatment with high dosage of corticosteroids, but relapse occurred when the prednisone dosage was tapered down to 10 mg/day. The patient was successfully treated with cyclosporin A with no recurrence of the disease in the last 2 years.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14740456

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  A case of pure red cell aplasia and systemic lupus erythematosus caused by human parvovirus B19 infection.

Authors:  Haruko Ideguchi; Shigeru Ohno; Yoshiaki Ishigatsubo
Journal:  Rheumatol Int       Date:  2006-10-07       Impact factor: 2.631

2.  Isoniazid-triggered pure red cell aplasia in systemic lupus erythematosus complicated with myasthenia gravis.

Authors:  Hideki Nakamura; Akitomo Okada; Atsushi Kawakami; Satoshi Yamasaki; Hiroaki Ida; Masakatsu Motomura; Daisuke Imanishi; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2009-08-25       Impact factor: 2.631

3.  Cyclosporine A responsive pure red cell aplasia in a child with systemic lupus erythematosus.

Authors:  Niranjan Biswal; Parameswaran Narayanan; Ginigeri Chetan
Journal:  Indian J Hematol Blood Transfus       Date:  2008-03-19       Impact factor: 0.900

Review 4.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.